Table 3.

Separate Multivariable Poisson Models Examining Effect of Percent of Time on Different Drug Regimens Stratified by Number of Years on Combination Antiretroviral Therapy on the Incidence of Kaposi Sarcoma

Drug Type	Year of Combination Antiretroviral Therapy Use	Incidence Rate Ratioa	P Value
Boosted PI	1	1.01 (0.90–1.14)	.89
(per additional 10% time)	2	0.95 (0.79–1.13)	.54
	3	0.79 (0.69–0.90)	<.001
Nonnucleoside reverse transcriptase inhibitor	1	0.96 (0.89–1.03)	.22
(per additional 10% time)	2	1.09 (1.00–1.20)	.06
	3	0.98 (0.92–1.04)	.53
Nelfinavir	1	0.99 (0.91–1.07)	.78
(per additional 10% time)	2	1.08 (0.96–1.21)	.21
	3	1.00 (0.93–1.08)	.98
Nonboosted PI	1	1.09 (0.99–1.19)	.07
(per additional 10% time)	2	1.00 (0.83–1.22)	.97
	3	1.02 (0.91–1.16)	.71

Abbreviation: PI, protease inhibitor.

^a Adjusted for age, race, Deyo comorbidity score, clinic visits/year, % of time on combination antiretroviral therapy (cART), era of human immunodeficiency virus (HIV) diagnosis, lowest CD4 count before cART, CD4 count at event/censor, HIV viral load, and time from initiating cART.